| 103.45 -1.59 (-1.51%) | 09-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 134.27 | 1-year : | 144.15 |
| Resists | First : | 114.96 | Second : | 123.41 |
| Pivot price | 111.75  |
|||
| Supports | First : | 101.28 | Second : | 84.27 |
| MAs | MA(5) : | 104.87 |
MA(20) : | 112.72 |
| MA(100) : | 118.15 |
MA(250) : | 115.03 |
|
| MACD | MACD : | -4.1 |
Signal : | -3.1 |
| %K %D | K(14,3) : | 20 |
D(3) : | 16.9 |
| RSI | RSI(14): 36 |
|||
| 52-week | High : | 148.83 | Low : | 69.8 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ABVX ] has closed above bottom band by 12.2%. Bollinger Bands are 30.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 105.92 - 106.53 | 106.53 - 107.18 |
| Low: | 100.85 - 101.51 | 101.51 - 102.23 |
| Close: | 102.2 - 103.35 | 103.35 - 104.61 |
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Mon, 21 Sep 2026
Abivax (ABVX) raises €767M as lead colitis drug targets Q4 2026 FDA filing - stocktitan.net
Mon, 21 Sep 2026
Abivax SA (ABVX) Reports H1 2026 Results, Names New CMO and CTO - TradingView
Mon, 21 Sep 2026
Abivax SA (ABVX) Reports H1 2026 Results, Management Changes - TradingView
Mon, 21 Sep 2026
Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Mon, 21 Sep 2026
Accenture, Abivax and 3 Stocks to Watch Heading Into Monday - Benzinga
Mon, 21 Sep 2026
Abivax SA (ABVX) JUN/2026 Earning Prediction - Intellectia AI
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 7.014e+007 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4,020 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.54e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 183.7 % |
| Return on Equity (ttm) | -44.7 % |
| Qtrly Rev. Growth | 4.92e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -5.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -178 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.1 |
| Dividend | 0 |
| Forward Dividend | 6e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|